<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748889</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1380</org_study_id>
    <nct_id>NCT02748889</nct_id>
  </id_info>
  <brief_title>Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>An Open Label, Randomized Phase I/II Trial of Carboplatin Plus Etoposide With ot Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giuseppe Giaccone</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study with two parts, a Phase I study and a randomized Phase II study.
      This study will be conducted at approximately ten sites in the United States. Approximately
      178 patients will be enrolled in this trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combining standard chemotherapy with a PD-1/PD-L1 inhibitor holds great appeal in the
      treatment of SCLC. While this approach may be appropriate for many cancer types, SCLC may be
      particularly vulnerable to this treatment strategy. Early studies have suggested greater
      efficacy with agents targeting PD-1/PD-L1 in tumors that are more mutationally complex, such
      as those associated with tobacco use. SCLC has a strong association with tobacco use and
      indeed, genome-wide sequencing studies have consistently shown that SCLC carries one of the
      highest rates of non-synonymous mutations. In addition, MPDL3280A has been safely combined
      with platinum based chemotherapy doublets in the treatment of NSCLC. Thus, a combination of
      carboplatin, etoposide and MPDL3280A may significantly improve outcomes in the treatment of
      SCLC.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties with recruitment
  </why_stopped>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 9, 2017</completion_date>
  <primary_completion_date type="Actual">May 9, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) With Carboplatin, Etoposide and MPDL3280A Compared to Chemotherapy Alone According to RECIST v1.1</measure>
    <time_frame>From the first occurrence of progression or death, whichever occurred first, assessed up to 2 years.</time_frame>
    <description>Disease progression will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT and bone scans.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Small Cell Lung Cancer ( SCLC )</condition>
  <arm_group>
    <arm_group_label>Carboplatin plus etoposide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin, etoposide and MPDL3280A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Standard chemotherapy</description>
    <arm_group_label>Carboplatin plus etoposide</arm_group_label>
    <arm_group_label>Carboplatin, etoposide and MPDL3280A</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Standard chemotherapy</description>
    <arm_group_label>Carboplatin plus etoposide</arm_group_label>
    <arm_group_label>Carboplatin, etoposide and MPDL3280A</arm_group_label>
    <other_name>VP-16, Toposar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MPDL3280A</intervention_name>
    <description>Experimental biologic</description>
    <arm_group_label>Carboplatin, etoposide and MPDL3280A</arm_group_label>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent Form (ICF)

          -  Ability and willingness to comply with the requirements of the study protocol

          -  Age 18 years or older

          -  Histological or cytological diagnosis of ES-SCLC (Note: Extensive-stage disease is
             defined as disease beyond the ipsilateral hemithorax, mediastinum and ipsilateral
             supraclavicular area and including malignant pleural or pericardial effusion or
             hematogenous metastases)

          -  Patients with mixed histology SCLC and NSCLC are permitted

          -  Representative tumor specimens in paraffin blocks (preferred) or at least 10 unstained
             slides, with an associated pathology report, requested at any time prior to study
             entry. Tissue from core needle, punch, or excisional biopsy sample collection is
             preferred but slides from fine needle aspiration, brushing, and lavage samples are
             acceptable.

          -  Adequate hematologic and end organ function, defined by the following laboratory
             results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1)

          -  ANC 1000 cells/mL

          -  WBC counts 2500/mL

          -  Lymphocyte count 500/mL

          -  Platelet count 100,000/mL

          -  Hemoglobin 9.0 g/dL (transfusion to meet this criterion is permitted)

          -  Serum sodium greater than 120 mmol/L

          -  Total bilirubin must be 1.5 ULN with the following exception:

        Patients with known Gilbert disease who have serum bilirubin level 3 ULN may be enrolled.

        - AST and ALT 3.0 ULN with the following exception: Patients with liver involvement: AST
        and/or ALT 5 ULN

        - Alkaline phosphatase 2.5 ULN with the following exception:

        Patients with liver or bone inv ULN or creatinine clearance 50 mL/min on the basis of the
        Cockcroft-Gault glomerular filtration rate estimation:

        (140 age) (weight in kg) (0.85 if female) 72 (serum creatinine in mg/dL)

          -  Measurable disease per RECIST v1.1 (see Appendix 6)

          -  Patients with asymptomatic CNS metastases are allowed

          -  For female patients of childbearing potential and male patients with partners of
             childbearing potential, agreement (by patient and/or partner) to use highly effective
             form(s) of contraception (i.e., one that results in a low failure rate [ 1 percent per
             year] when used consistently and correctly) and to continue its use for 6 months after
             the last dose of MPDL3280A

          -  ECOG performance status of 0 or 1 (see Appendix 8)

          -  Patients with ECOG performance status of 2, secondary to the underlying disease, may
             be enrolled in the Phase II portion of the study

          -  INR and aPTT within 1.5 ULN

          -  This applies only to patients who do not receive therapeutic anticoagulation; patients
             receiving therapeutic anticoagulation (such as low molecular weight heparin or
             warfarin) should be on a stable dose.

        Exclusion Criteria:

          -  Inability to comply with study and follow-up procedures

          -  Limited stage SCLC appropriate for definitive treatment with chemoradiation

          -  Prior systemic anti-cancer therapy for small cell lung cancer

          -  Prior palliative radiation therapy less than 2 weeks prior to administration of study
             treatment or prior whole brain radiation therapy (WBRT) less than 4 weeks prior to
             study treatment

          -  Symptomatic brain metastases (patients with asymptomatic brain metastases may be
             eligible provided other criteria are met)

          -  Leptomeningeal disease or carcinomatous meningitis

          -  Uncontrolled hypercalcemia ( â‰¥1.5 mmol/L ionized calcium or Ca &gt; 12 mg/dL) or
             symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or
             denosumab (patients receiving bisphosphonate therapy or denosumab to prevent skeletal
             events and who do not have a history of clinically significant hypercalcemia are
             eligible, though patients receiving denosumab must be willing and eligible to receive
             bisphosphonates instead)

          -  Malignancies other than SCLC within 2 years prior to administration of study treatment
             with the exception of those with a negligible risk of metastases or death treated with
             expected curative outcome (such as adequately treated carcinoma in situ of the cervix
             or breast, basal or squamous cell skin cancer, or localized prostate cancer treated
             definitively)

          -  Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, cirrhosis, fatty liver, and inherited liver disease

          -  Pregnancy, lactation, or breastfeeding

          -  History or risk of autoimmune disease, including but not limited to systemic lupus
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's
             syndrome, Bell's palsy, Guillain-BarrÃ© syndrome, multiple sclerosis, autoimmune
             thyroid disease, vasculitis, or glomerulonephritis

          -  Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid
             replacement hormone may be eligible.

          -  Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be
             eligible.

          -  Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with
             dermatologic manifestations only (e.g., patients with psoriatic arthritis would be
             excluded) are permitted provided that they meet the following conditions:

          -  Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular
             manifestations

          -  Rash must cover less than 10% of body surface area (BSA)

          -  Disease is well controlled at baseline and only requiring low potency topical steroids
             (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide
             0.05%, aclometasone dipropionate 0.05%)

          -  No acute exacerbations of underlying condition in the last 12 months (not requiring
             PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, biologics, oral
             calcineurin inhibitors, high potency oral steroids)

          -  History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced),
             organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing
             pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan

          -  History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

          -  History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C
             infection

          -  Patients with past or resolved hepatitis B infection (defined as having a negative
             hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to
             hepatitis B core antigen] antibody test) are eligible.

          -  Patients positive for HCV antibody are eligible only if polymerase chain reaction
             (PCR) is negative for HCV RNA.

          -  Active, clinically serious infections of NCI CTCAE v4.0 Grade 2 or higher within 4
             weeks prior to Cycle 1, Day 1

          -  Significant cardiovascular disease, such as New York Heart Association cardiac disease
             (Class II or greater), myocardial infarction within the previous 3 months, unstable
             arrhythmias, or unstable angina. Patient with known coronary artery disease,
             congestive heart failure not meeting the above criteria, or known left ventricular
             ejection fraction less than 50% must be on a stable medical regimen that is optimized
             in the opinion of the treating physician

          -  Major surgical procedure within 28 days prior to Cycle 1, Day 1 or anticipation of
             need for a major surgical procedure during the course of the study

          -  History of stroke or transient ischemic attack (TIA) within 6 months prior to Cycle 1,
             Day 1

          -  Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study

          -  Influenza vaccination should be given during influenza season only (approximately
             October to March). Patients must not receive live, attenuated influenza vaccine (e.g.,
             FluMist) within 4 weeks prior to Cycle 1, Day 1 or at any time during the study.

          -  Treatment with systemic immunostimulatory agents (including but not limited to IFN ,
             IL-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to
             Cycle 1, Day 1

          -  Prior treatment with antiPD-1, or antiPD-L1 therapeutic antibody or pathway targeting
             agents

          -  Patients who have received prior treatment with antiCTLA-4 may be enrolled, provided
             the following requirements are met:

          -  Minimum of 12 weeks from the first dose of antiCTLA-4 and 6 weeks from the last dose

          -  No history of severe immune-related adverse effects from anti CTLA 4 (CTCAE Grade 3
             and 4)

          -  Treatment with investigational agent within 4 weeks prior to Cycle 1, Day 1 (or within
             five half lives of the investigational product, whichever is longer)

          -  Treatment with systemic immunosuppressive medications (including but not limited to
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti tumor
             necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1

          -  Patients who have received acute, low dose, systemic immunosuppressant medications
             (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.

          -  The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for
             patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins

          -  Known hypersensitivity to Chinese hamster ovary cell products or other recombinant
             human antibodies

          -  Patients with prior allogeneic bone marrow transplantation or prior solid organ
             transplantation

          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe ( Beppe) Giaccone, Md,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Georgetown Lombardi Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, FrÃ¼h M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012 May 10;30(14):1692-8. doi: 10.1200/JCO.2011.40.4905. Epub 2012 Apr 2. Review.</citation>
    <PMID>22473169</PMID>
  </reference>
  <reference>
    <citation>Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr;54(4):307-14. Epub 2004 Dec 15. Review.</citation>
    <PMID>15599732</PMID>
  </reference>
  <reference>
    <citation>Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007 May;56(5):739-45. Epub 2006 Dec 29. Review.</citation>
    <PMID>17195077</PMID>
  </reference>
  <reference>
    <citation>Brahmer J, Reckamp KL, Baas P, CrinÃ² L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, ArÃ©n Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.</citation>
    <PMID>26028407</PMID>
  </reference>
  <reference>
    <citation>Segal, N.H., et al., Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J Clin Oncol, 2014. 32(5S): p. abstr 3002</citation>
  </reference>
  <reference>
    <citation>Lutzky, J., et al., A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. J Clin Oncol, 2014. 32(5S): p. abstr 3001</citation>
  </reference>
  <reference>
    <citation>Antonia, S.J., et al., Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol, 2015. 33: p. abstr 7503</citation>
  </reference>
  <reference>
    <citation>Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.</citation>
    <PMID>22658128</PMID>
  </reference>
  <reference>
    <citation>Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM, Lynch TJ. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.</citation>
    <PMID>22858559</PMID>
  </reference>
  <reference>
    <citation>Liu, S.V., et al., Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2015. 33: p. abstr 8030</citation>
  </reference>
  <reference>
    <citation>Powderly, J.D., et al., Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol, 2013. suppl; abstr 3001</citation>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <results_first_submitted>April 24, 2018</results_first_submitted>
  <results_first_submitted_qc>June 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2018</results_first_posted>
  <last_update_submitted>June 29, 2018</last_update_submitted>
  <last_update_submitted_qc>June 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Giuseppe Giaccone</investigator_full_name>
    <investigator_title>Associate Director for Clinical Research</investigator_title>
  </responsible_party>
  <keyword>SCLC</keyword>
  <keyword>Small Cell</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>MPDL3280A</keyword>
  <keyword>atezolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02748889/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carboplatin Plus Etoposide</title>
          <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
Carboplatin: Standard chemotherapy
Etoposide: Standard chemotherapy</description>
        </group>
        <group group_id="P2">
          <title>Carboplatin, Etoposide and MPDL3280A</title>
          <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
Carboplatin: Standard chemotherapy
Etoposide: Standard chemotherapy
MPDL3280A: Experimental biologic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This study enrolled one subject before being terminated early due to recruitment difficulties.That subject was assigned to the Carboplatin, Etoposide, and MPDL3280A arm. No subjects were enrolled to the Carboplatin and Etoposide arm</population>
      <group_list>
        <group group_id="B1">
          <title>Carboplatin Plus Etoposide</title>
          <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
Carboplatin: Standard chemotherapy
Etoposide: Standard chemotherapy</description>
        </group>
        <group group_id="B2">
          <title>Carboplatin, Etoposide and MPDL3280A</title>
          <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
Carboplatin: Standard chemotherapy
Etoposide: Standard chemotherapy
MPDL3280A: Experimental biologic</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="58" spread="0"/>
                    <measurement group_id="B3" value="58" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) With Carboplatin, Etoposide and MPDL3280A Compared to Chemotherapy Alone According to RECIST v1.1</title>
        <description>Disease progression will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT and bone scans.</description>
        <time_frame>From the first occurrence of progression or death, whichever occurred first, assessed up to 2 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, Etoposide and MPDL3280A</title>
            <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
Carboplatin: Standard chemotherapy
Etoposide: Standard chemotherapy
MPDL3280A: Experimental biologic</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) With Carboplatin, Etoposide and MPDL3280A Compared to Chemotherapy Alone According to RECIST v1.1</title>
          <description>Disease progression will be assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT and bone scans.</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for each subject from the time they signed the informed consent until study completion. The period of collection depended on the length of the treatment period. For the single subject enrolled, this amounted to 6.5 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carboplatin, Etoposide and MPDL3280A</title>
          <description>Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
Carboplatin: Standard chemotherapy
Etoposide: Standard chemotherapy
MPDL3280A: Experimental biologic</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Increased bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>ALT Elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Giuseppe Giaccone</name_or_title>
      <organization>Georgetown University Medical Center - Lombardi Comprehensive Cancer Center</organization>
      <phone>202-687-7072</phone>
      <email>gg496@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

